Table 4.

Univariate and multivariate logistic regression analysis of risk factors associated with 30-day mortality in patients with Acinetobacter calcoaceticus-Acinetobacter baumannii complex bacteremia.

			Univariate analysis		Multivariate analysis
Risk factor	Survived (n = 101)	Died (n = 46)	OR (95% CI)	p-value	OR (95% CI)	p-value
Age, mean ± (SD)	51 (17)	56 (12)	1.02 (1.00–1.05)	0.06
Sex, female	54 (54)	14 (30)	0.38 (0.18–0.80)	0.01	0.24 (0.08–0.75)	0.01
A. baumannii	74 (73)	42 (91)	3.83 (1.26–11.7)	0.02
Source:
Catheter	76 (75)	26 (57)	0.43 (0.21–0.89)	0.02
Respiratory	3 (3)	11 (24)	10.27 (2.71–38.96)	< 0.01
Primary	10 (10)	1 (2)	0.20 (0.03–1.63)	0.13
Healthcare-associated	46 (46)	39 (85)	6.67 (2.72–16.3)	< 0.01
Multidrug resistance	54 (54)	43 (94)	12.48 (3.63–42.85)	< 0.01
Received appropriate therapy	91 (90)	25 (54)	0.13 (0.06–0.31)	< 0.01	0.13 (0.04–0.44)	< 0.01
Days to appropriate therapy, median (range)	1 (0–13)a	1 (0–5)b	0.84 (0.64–1.12)	0.24
Mechanical ventilation	16 (16)	36 (78)	19.13 (7.93–46.15)	< 0.01	20.7 (6.8–62.9)	< 0.01
Prior antibiotic days, median (range)	0 (0–42)	12 (0–105)	1.09 (1.05–1.13)	< 0.01
Age-adjusted Charlson comorbidity score, median (range)	3 (0–12)	5 (0–11)	1.16 (1.03–1.31)	0.01
Current immunosuppression	46 (46)	33 (72)	3.04 (1.43–6.44)	< 0.01
Diabetes mellitus	27 (27)	21 (46)	2.3 (1.11–4.77)	0.03
Renal dysfunction	35 (35)	34 (74)	5.34 (2.46–11.6)	< 0.01	4.21 (1.46–12.1)	< 0.01
Liver dysfunction	23 (23)	27 (59)	4.82 (2.28–10.19)	< 0.01

Data are No. (%) unless otherwise specified

OR, odds ratio; CI, confidence interval; SD, standard deviation; ICU, intensive care unit

^aFor the 91 survivors who received appropriate therapy

^bFor the 25 non-survivors who received appropriate therapy